A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

被引：2
|
作者：
Jaenne, P. A. [1 ]
Ahn, M. -J. [2 ]
Kim, D. -W. [3 ]
Kim, S. -W. [4 ]
Planchard, D. [5 ]
Ramalingam, S. S. [6 ]
Frewer, P. [7 ]
Cantarini, M. [8 ]
Ghiorghiu, S. [9 ]
Yang, J. C. -H. [10 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med,Hematol,Oncol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Gustave Roussy, Dept Med Oncol & Translat Res, Thorac Unit, Villejuif, France
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] Astra Zeneca, ECD Biometr, Macclesfield, Cheshire, England
[8] Astra Zeneca, Global Med Dept, Oncol, Macclesfield, Cheshire, England
[9] Astra Zeneca, Global Med Dev, Luton, Herts, England
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv128.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
    Tsuchiya-Kawano, Yuko
    Sasaki, Tomonari
    Yamaguchi, Hiroyuki
    Hirano, Katsuya
    Horiike, Atsushi
    Satouchi, Miyako
    Hosokawa, Shinobu
    Morinaga, Ryotaro
    Komiya, Kazutoshi
    Inoue, Koji
    Fujita, Yuka
    Toyozawa, Ryo
    Kimura, Tomoki
    Takahashi, Kosuke
    Nishikawa, Kazuo
    Kishimoto, Junji
    Nakanishi, Yoichi
    Okamoto, Isamu
    ONCOLOGIST, 2020, 25 (06): : 475 - +
  • [43] HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
    Fang, W.
    Cappuzzo, F.
    Goldman, J. W.
    Zhao, Y.
    Huang, Y.
    Anderson, I.
    Masip, J. Remon
    Li, W.
    Xia, M.
    Li, J.
    James, D.
    Styles, L.
    West, H. L.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [44] Significance of lesions: single lesion, five lesions and whole body lesions, in prediction of Progression Free Survival (PFS) & Overall Survival (OS) and response evaluation in NSCLC patients treated with EGFR tyrosine kinase inhibitor therapy by PERCIST criteria - A comparative prospective study
    Bhoil, A.
    Mittal, B. R.
    Kashyap, R.
    Singh, B.
    Singh, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S466 - S466
  • [45] Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Yang, J-J.
    Pavlakis, N.
    Xie, F.
    Li, T.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2024, 35 : S813 - S813
  • [46] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Meletios Dimopoulos
    Michael Wang
    Vladimir Maisnar
    Jiri Minarik
    William Bensinger
    Maria-Victoria Mateos
    Mihaela Obreja
    Julie Blaedel
    Philippe Moreau
    Journal of Hematology & Oncology, 11
  • [47] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Dimopoulos, Meletios
    Wang, Michael
    Maisnar, Vladimir
    Minarik, Jiri
    Bensinger, William
    Mateos, Maria-Victoria
    Obreja, Mihaela
    Blaedel, Julie
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [48] AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)
    Zhou, C.
    Wang, M.
    Cheng, Y.
    Chen, Y.
    Zhao, Y.
    Shi, Y-K.
    Ahn, M-J.
    Lu, Y.
    Shi, M.
    Han, J-Y.
    Kim, S-W.
    Zhang, H-L.
    Chen, G.
    Li, H.
    Wang, J.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Correlation of Progression-Free Survival (PFS) with Early Response of Biomarkers Chromogranin A (CgA) and 5-Hhydroxyindoleacetic Acid (5-HIAA) Levels in Patients with Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
    Wolin, Edward
    Castellano, Daniel
    Kaltsas, Gregory
    Gross, David
    Panneerselvam, Ashok
    Klimovsky, Judith
    Saletan, Stephen
    Yao, James
    Baudin, Eric
    PANCREAS, 2012, 41 (02) : 350 - 351
12345